Breztri Aerosphere approved in the US for the maintenance treatment of COPD.- AstraZeneca

AstraZeneca’s Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) has been approved in the US for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

The approval by the FDA was based on positive results from the Phase III ETHOS trial in which Breztri Aerosphere, a triple-combination therapy, showed a statistically significant reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies Bevespi Aerosphere (glycopyrrolate/formoterol fumarate) and PT009 (budesonide/formoterol fumarate). The approval was also supported by efficacy and safety data from the Phase III KRONOS trial.

Results from the Phase III ETHOS trial were published in The New England Journal of Medicine in June 2020 and results from the Phase III KRONOS trial were published in The Lancet Respiratory Medicine in September 2018. In both trials, the safety and tolerability of Breztri Aerosphere were consistent with the profiles of the dual comparators.

Breztri Aerosphere is not indicated for the relief of acute bronchospasm or for the treatment of asthma in the US or other countries. Breztri Aerosphere is approved in Japan and China for patients with COPD and under regulatory review in the EU.